IQVIA Asia Pacific has signed a Memorandum of Understanding with the NUS Academy for Healthy Longevity (NUS-AHL).
Through this partnership, the aim is to advance Healthy Longevity Medicine (HLM) through joint research, information exchange, and development of new technologies, to potentially bring “substantial benefits to society”.
The collaboration will focus on personalised health innovations, public education, policy shaping, and global partnerships to address the challenges posed by ageing populations and enhance healthcare outcomes.
“As the world ages, the demand for longevity medicine and geroscience development increases. IQVIA’s mission is to accelerate innovation to create a healthier world and actualise smarter healthcare for everyone, everywhere. Similarly, NUS-AHL is dedicated to adding healthy years of life by delaying ageing, prolonging disease-free life, and maintaining high functionality.
“When IQVIA learned about the planning of a Centre for Healthy Longevity Research in Singapore, IQVIA’s dedicated Consumer Health team recognised a strong synergy in the mission and vision of both organisations.
“We aim to revolutionise approaches to ageing and health by combining the Academy’s expertise in longevity medicine with IQVIA’s capabilities to connect intelligence and co-create innovative initiatives to power everyday health from concept to commercialisation,” IQVIA Asia Pacific told NutraIngredients-Asia.
In addition, the two organisations share the goal of empowering self-care and reducing the burden of ageing, including optimisation of healthspan and prevention of age-related diseases.
Realising this goal requires a multi-disciplinary approach, “as ageing affects all facets of life, not just health”.
“Through various initiatives planned, the collaboration aims to improve the overall quality of life for individuals and society as a whole. This is driven by the need to address the challenges faced by an ageing population and to develop innovative solutions that cater to the unique needs of everyone, especially the older adults.”
NUS and IQVIA will embark on several joint efforts, with the first project involving the use of the latter’s fit-for-purpose technology platform specifically built to efficiently conduct Patient Reported Outcome (PRO) research and data management, enabling NUS-AHL to focus on scientific planning and study execution.
“Additionally, we are currently exploring the use of generative AI in longevity research, aiming to investigate and validate the use of advanced analytics and cutting-edge technology to improve evidence-based care in the emerging field of HLM.”
Key areas of progress
Specifically, NUS and IQVIA aim to make progress in several key areas in the near future.
These include evidence-based healthspan extension research, which involves the investigation and generation of scientific evidence to empower people to age healthily and “not spend the later years of life in sickness”. This would be done through collaborative studies on intervention, policy, and education.
The organisations are also planning to “work with the industry” to co-develop innovative healthcare and self-care solutions, particularly to improve quality of life.
Furthermore, the partnership seeks to further the fields of geroscience (study of the link between ageing processes and chronic diseases) and precision geromedicine through joint research and development of new technologies and biomarkers.
“[Another key area] is to establish connections with other longevity research centres and industry players to foster international collaborations and advance the field of healthy ageing on a global scale.”
